Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Bestlife Regenerative Medicine is a private China-based regenerative medicine and biomaterials company focused on in-situ tissue regeneration. The company develops and manufactures regenerative medical materials built around its proprietary RegeSi technology, described as a calcium phosphosilicate-based bioactive material platform intended to support bone regeneration, wound healing, scar-free deep wound repair, dental repair, and broader organ and tissue regeneration. Available public information indicates the business is oriented more toward biomaterials and medical-device-style regenerative products than toward a traditional therapeutic drug pipeline. The company appears to have built GMP-compliant cleanroom manufacturing capacity and has received Chinese government support and recognition as a high-tech enterprise. Its activities also include patenting formulations and materials for wound care, oral repair, and other regenerative applications.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Bestlife Regenerative Medicine.